Evidence based guidelinelines for treatment of primary headaches-2012 update

Acta Clinica Croatica

Volumn 51, Issue 3, 2012, Pages 323-378

  Cvetković, Vlasta Vuković ^a   Kes, Vanja Bašić ^a   Šerić, Vesna ^a   Solter, Vesna Vargek ^a   Demarin, Vida ^a   Jančuljak, Davor ^b   Petravić, Damir ^c   Lakušić, Darija Mahović ^c   Hajnšek, Sanja ^c   Lušić, Ivo ^d   Bielen, Ivan ^e   Bašić, Silvio ^f   Sporiš, Davor ^f   Soldo, Silva Butković ^b   Antončić, Igor ^g  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d UNIVERSITY HOSPITAL SPLIT   (Croatia)

^e University Hospital Sveti Duh   (Croatia)

^f University of Zagreb   (Croatia)

^g KBC RIJEKA   (Croatia)

Author keywords

Cluster headache; Headache treatment; Migraine; Pharmacotherapy; Tension type headache

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS PARACETAMOL; ANTIEMETIC AGENT; CAFFEINE; CAFFEINE PLUS PARACETAMOL PLUS PROPYPHENAZONE; CHLORPROMAZINE; DEXAMETHASONE; DICLOFENAC; DOMPERIDONE; ERGOT ALKALOID; GRANISETRON; HYDROCORTISONE; IBUPROFEN; KETOROLAC; METOCLOPRAMIDE; NAPROXEN; NARATRIPTAN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PLACEBO; PROBABLE TENSION HEADACHE; PROCHLORPERAZINE; SUMATRIPTAN; THIETHYLPERAZINE; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZATOSETRON; ZOLMITRIPTAN;

ABNORMAL BLOOD PRESSURE; ACUTE CORONARY SYNDROME; AKATHISIA; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN ARTERY ANEURYSM; CEREBROVASCULAR DISEASE; CHRONIC TENSION HEADACHE; CLINICAL DECISION MAKING; CLINICAL FEATURE; CROATIA; DIAGNOSTIC ACCURACY; DIZZINESS; DROWSINESS; DRUG HYPERSENSITIVITY; DYSTONIA; EAR NOSE THROAT DISEASE; ELECTROENCEPHALOGRAPHY; EPISODIC TENSION HEADACHE; ERYTHEMA; EVIDENCE BASED PRACTICE; FACE PAIN; FATIGUE; FLUSHING; HEAD INJURY; HEADACHE; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE REACTION; LABORATORY TEST; LIVER FUNCTION TEST; LUMBAR PUNCTURE; MEDICAL SOCIETY; MENTAL DISEASE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINOUS INFARCTION; NAUSEA; NAUSEA AND VOMITING; NECK INJURY; NEURALGIA; NEUROIMAGING; NEUROLOGIC EXAMINATION; OCULOGYRIC CRISIS; PHYSICIAN; PRACTICE GUIDELINE; RETINAL MIGRAINE; SEDATION; SEIZURE; SIDE EFFECT; SKIN TINGLING; STATUS MIGRAINOSUS; SUBARACHNOID HEMORRHAGE; TRANSFORMED MIGRAINE; WEAKNESS; CLASSIFICATION; EVIDENCE BASED MEDICINE;

EVIDENCE-BASED MEDICINE; HEADACHE; HUMANS;

MLCS; MLOWN;

EID: 84873718106     PISSN: 03539466     EISSN: 13339451     Source Type: Journal    
DOI: None     Document Type: Article

References (317)

1. Headache Classifcation Subcommittee of the international headache Society. Te international Classifcation of head¬ache Disorders, 2nd edn. Cephalalgia 2004;24(Suppl 1):14-5.
2. GOADSBY P, OLESEN J. Diagnosis and management of migraine. BMJ 1996;312:1279-83.
3. DEMARIN V, VUKOVIC V, LOVRENCIC HUZJAN A, LUŠIC I, JANCULJAK D, WILHEIM K, ZURAK N. ev¬idence based guidelines for treatment of primary headaches. Acta Clin Croat 2005;44:139-83.
4. American College of emergency physicians (ACep). Clini-cal policy: critical issues in the evaluation and management of patients presenting to the emergency department with acute headache. Ann emerg Med 2002;39:108-22.
5. SILBERSTEIN SD, SAPER JR, FREITAG FG. Migraine: diagnosis and treatment. in: SilBeRStein SD, lip-ton RB, DAleSSio DJ, editors. Wolf's headache and other head pain, 7th edn. oxford: oxford university press, 2 0 01:1 2 1-2 37.
6. FRISHBERG BM, ROSENBERG JH, MATCHAR DB, MCCRORY DC, PIETRZAK MP, ROZEN TD, SILBER-STEIN SD. evidence-based guidelines in the primary care setting: neuroimaging in patients with nonacute headache. Available at: http://www.aan.com.
7. EDMEADS J, MACKELL JA. Te economic impact of migraine: an analysis of direct and indirect costs. headache 2002;42:501-509.
8. STOVNER LJ, HAGEN K, JENSEN R, et al. Te global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210.
9. RASMUSSEN BK, STEWART WF. epidemiology of migraine. in: oleSen J, tfelt-hAnSen p, WelCh KMA, editors. Te headaches, 2nd edn. philadelphia: lippin-cott Williams & Wilkins, 2000;227-33.
10. SILBERSTEIN S, LODER E, DIAMOND S, REED ML, BIGAL ME, LIPTON RB; AMPP ADVISORY GROUP. prob¬able migraine in the united States: results of the American Migraine prevalence and prevention (AMpp) study. Cepha-lalgia 2007;27:220-34.
11. LIPTON RB, BIGAL ME, DIAMOND M, FREITAG F, REED ML, STEWART WF; AMPP ADVISORY GROUP. Mi¬graine prevalence, disease burden, and the need for preventive therapy. neurology 2007;30;68:343-9.
12. VUKOVIC V, PLAVEC D, PAVELIN S, JANCULJAK D, IVANKOVIC M, DEMARIN V. prevalence of migraine, probable migraine and tension type headache in Croatia. neuroepidemiology 2010;35:59-65.
13. STEWART WF, LIPTON RB, LIBERMAN J. variations in migraine prevalence by race. neurology 1996;47:52-9.
14. DUCROS A, TOURNIER-LASSERVE E, BOUSSER MG. Te genetics of migraine. lancet neurol 2002;5:285-93. 15.SAMAAn Z, gAySinA D, Cohen-WooDS S, CRADDoCK n, JoneS l, KoRSZun A, oWen M, Mente A, Mcguffin p, fARMeR A. Methylenetet-rahydrofolate reductase gene variant (MthfR C677t) and migraine: a case control study and meta-analysis. BMC neu-rol 2011;11:66.
15. SAMAAN Z, GAYSINA D, COHEN-WOODS S, CRADDOCK N, JONES L, KORSZUN A, OWEN M, MENTE A, MCGUFFIN P, FARMER A. Methylenetet-rahydrofolate reductase gene variant (MthfR C677t) and migraine: a case control study and meta-analysis. BMC neu-rol 2011;11:66.
16. SILBERSTEIN SD. treatment recommendations for mi¬graine. nat Clin pract neurol 2008;4:482-9. epub 2008 Jul 29.
17. METT A, TFELT - HANSEN P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr opin neurol 2008;21:331-7.
18. TFELT - HANSEN P. A review of evidence-based medi¬cine and meta-analytic reviews in migraine. Cephalalgia 2006;26:1265-74.
19. EVANS R, ROZEN TD, ADELMAN JU. neuroimag-ing and other diagnostic testing in headache. in: SilBeR-Stein SD, lipton RB, DAleSSio DJ, editors. Wolf's headache and other head pain, 7th edn. oxford: oxford uni¬versity press, 2001:27-49.
20. SANDRINI G, FRIBERG L, COPOLLA G, et al. neu-rophysiological tests and neuroimaging procedures in non-acute headache. efnS guidelines, 2nd edn. eur J neurol 2011;18:373-81.
21. JAMIESON DG, HARGREAVES R. Te role of neuroim-aging in headache. J neuroimaging 2002;12:42-51.
22. TASSORELLI C, SANCES G, ALLENA M, GHIOTTO N, BENDTSEN L, OLESEN J, NAPPI G, JENSEN R. Te usefulness and applicability of a basic headache diary be¬fore frst consultation: results of a pilot study conducted in two centres. Cephalalgia 2008;28:1023-30. epub 2008 Jul 8.
23. MACGREGOR EA. Menstrual migraine: a clinical review. J fam plann Reprod health Care 2007;33:36-47.
24. NEUHAUSER H, LEOPOLD M, VON BREVERN M, ARNOLD G, LEMPERT T. Te interrelations of migraine, vertigo and migrainous vertigo. neurology 2001;56:436-41.
25. NEUHAUSER HK, RADTKE A, VON BREVERN M, et al. Migrainous vertigo: prevalence and impact on quality of life. neurology 2006;26:1028-33.
26. VUKOVIC V, PLAVEC D, GALINOVIC I, LOVRENCIC HUZJAN A, BUDIŠIC M, DEMARIN V. prevalence of vertigo, dizziness and migrainous vertigo in patients with mi¬graine. headache 2007;47:1427-35.
27. FORWARD SP, MCGRATH PJ, MACKINNON D, et al. Medication patterns of recurrent headache suferers: a com-munity study. Cephalalgia 1998;18:146-51.
28. VUKOVIC V, PLAVEC D, LOVRENCIC HUZJAN A, BUDIŠIC M, DEMARIN V. treatment of migraine and tension-type headache in Croatia. J headache pain 2 010 ;11: 227-34 .
29. LUŠIC I, BILIC I. triptani - prekretnica u lijecenju mi-grene. Acta Med Croat 2008; 62:173-8. (in Croatian)
30. HOLLAND S, SILBERSTEIN SD, FREITAG F, DOD-ICK DW, ARGOFF C, ASHMAN E. evidence-based guideline update: nSAiDs and other complementary treat¬ments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of neurology and the American headache Society. neurol¬ogy 2012;78:1346-53.
31. SILBERSTEIN SD, HOLLAND S, FREITAG F, DOD-ICK DW, ARGOFF C, ASHMAN E. evidence-based guideline update: pharmacologic treatment for episodic mi¬graine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of neurology and the American headache Society. neurology. 2012;78:1337-45.
32. LOVRENCIC HUZJAN A, HERCEG M, BILUŠIC M, IVANCAN V. lijekovi s ucinkom na živcani sustav. in: v R h o vA C B , editor. farmakoterapijski prirucnik, 4th edn. Zagreb: Medicinska naklada 2003:437-526. (in Croatian)
33. EVERS S, AFRA J, FRESE A, GOADSBY PJ, LINDE M, MAY A, SáNDOR PS; EUROPEAN FEDERATION OF NEURO¬LOGICAL SOCIETIES. efnS guideline on the drug treatment of migraine - revised report of an efnS task force. eur J neurol 2009;16:968-81.
34. LODER E, BURCH R, RIZZOLI P. Te 2012 AhS/ AAn guidelines for prevention of episodic Migraine: a summary and comparison with other recent clinical practice guidelines. headache 2012;52:930-45. doi: 10.1111/j.1526-4610.2012.02185.x.
35. KELLEY NE, TEPPER DE. Rescue therapy for acute mi¬graine. part 1: triptans, dihydroergotamine, and magnesium. headache 2012;52:114-28.
36. SUMELAHTI ML, MATTILA K, SILLANMäKI L, SUMANEN M. prescription patterns in preventive and abortive migraine medication. Cephalalgia 2011;31:1659-63. epub 2011 nov 24.
37. DIAMOND M, CA DY R. initiating and optimizing acute therapy for migraine: the role of patient-centered stratifed care. Am J Med 2005;118(Suppl 1):18S-27S.
38. NG-MAKD S, HUX H, CHEN YT, MA L. Acute migraine treatment with oral triptans and nSAiDs in a managed care population. headache 2008;48:1176-85.
39. CADY R, BANKS J, NETT RB. Multi-center comparison of response to a single tablet of sumatriptan 85 mg and naproxen 500 mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response survey. headache 2011;51:961-70. doi: 10.1111/j.1526-4610.2011.01912.x. epub 2011 May 17.
40. MAGIS D, SCHOENEN J. treatment of migraine: update on new therapies. Curr opin neurol 2011;24:203-10.
41. FRIEDMAN BW, MULVEY L, ESSES D, et al. Metoclo-pramide for acute migraine: a dose-fnding randomized clini¬cal trial. Ann emerg Med 2011;57:475-82.e1. epub 2011 Jan 12.
42. ROTHROCK J F. non-steroidal anti-infammatory drugs (nSAiDs) for acute migraine treatment. headache 2010;50:1635-6. doi: 10.1111/j.1526-4610.2010.01785.x.
43. TAYLOR FR, KANIECKI RG. Symptomatic treatment of migraine: when to use nSAiDs, triptans, or opiates. Curr treat options neurol 2011;13:15-27.
44. KIRTHI V, DERRY S, MOORE RA, MCQUAY HJ. Aspi¬rin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2010;4:CD008041.
45. RABBIE R, DERRY S, MOORE RA, MCQUAYHJ. ibuprofen with or without an antiemetic for acutemi-graine headaches in adults. Cochrane Database SystRev 2010;10:CD008039.
46. TFELT-HANSEN P, HENRY P, MULDER LJ, et al. Te efectiveness of combined oral lysine acetylsalicylate and me-toclopramide compared with oral sumatriptan for migraine. lancet 1995;346:923-6.
47. SILBERSTEIN SD, MCCRORY DC. Butalbital in the treatment of headache: history, pharmacology and efcacy. headache 2001;41:953-67.
48. SILBERSTEIN SD, MCCRORY DS. opioids. Cephalalgia 2000;20:854-64.
49. DERRY S, MOORE RA, MCQUAY HJ. paracetamol (ac-etaminophen) with or without an antiemetic for acute mi-graine headaches in adults. Cochrane Database Syst Rev 2010;11:CD008040.
50. SINGH A, ALTER HJ, ZAIA B. Does the addition of dexamethasone to standard therapy for acute migraine head-ache decrease the incidence of recurrent headache for pa-tients treated in the emergency department? A meta-analysis and systematic review of the literature. Acad emerg Med 2008;15:1223-33. epub 2008 oct 25.
51. COLMAN I, FRIEDMAN BW, BROWN MD, et al. par-enteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008;336(7657):1359-61. epub 2008 Jun 9.
52. JONES J, SKLAR D, DOUGHERTY J, WHITE W. Ran¬domized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989;261:1174-6.
53. KOSTIC MA, GUTIERREZ FJ, RIEG TS, MOORE TS, GENDRON RT. A prospective, randomized trial of intra¬venous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann emerg Med 2010;56:1-6. epub 2010 Jan 4.
54. CARPAY JA, LINSSEN HJP, KOEHLER JJ, ARENDS LR, TIEDINK HGM. efcacy of sumatriptan nasal spray in recurrent migrainous headache: an open prospective study. headache 2003;43:395-9.
55. TFELT-HANSEN P. efcacy and adverse events of subcu¬taneous, oral and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998;18:532-8.
56. TFELT-HANSEN P. A comparative review of pharmacol¬ogy, pharmacokinetics and efcacy of triptans in migraine. Drugs 2000;6:1259-87.
57. KLASSEN A, ELKIND A, ASGHARNEJAD M, WEBSTER C, LAURENZA A. naratriptan is efective and well tolerated in the acute treatment of migraine. Results of a dou¬ble-blind, placebo-controlled, parallel group study. headache 1997;37:64 0 -5.
58. BLOCK GA, GOLDSTEIN J, POLIS A, REINES SA, SMITH ME. Te Rizatriptan Multicenter Study group. ef-cacy and safety of rizatriptan versus standard care during long-term treatment for migraine. headache 1998;38:764-71.
59. KRAMER MS, MATZURA-WOLFE D, POLIS A, GET-SON A, AMARENI PG, SOLBACH MP, et al. A placebo-controlled cross-over study of rizatriptan in the treatment of multiple migraine attacks. neurology 1998;51:773-81.
60. MATHEW NT. oral Almotriptan Study group. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. headache 2002;42:32-40.
61. PFAFFENRATH V, CUNIN G, SJONELL G, PREN-DERGAST S. efcacy and safety of sumatriptan tablets (25 mg, 50 mg and 100 mg) in the acute treatment of migraine; defning the optimum doses for oral sumatriptan. headache 1998;38:184-90.
62. DAHLOF C, FABRI M, LOFTUS J, JONES M, MANS-BACH H, SCOTT A. triptan efcacy and preference: results of a randomized, multi-centre, open-label, crossover study of sumatriptan, naratriptan, rizatriptan and zolmitriptan tablets in acute treatment of migraine. Cephalalgia 2001;21:410.
63. DOWSON AJ, BOES-HANSEN S, FARKKILA AM. Zolmitriptan nasal spray is fast-acting and highly efective in the acute treatment of migraine. eur J neurol 2000;7(Suppl 3):82.
64. SARGENT J, KIRCHNER JR, DAVIS R, KIRKHART B. oral sumatriptan is efective and well tolerated for the acute treatment of migraine: results of a multicenter study. neurol-ogy 1995;45(Suppl 7):10-4.
65. DAHLOF C, DIENER HC, GOADSBY PJ, MASSIOU H, OLESEN J, SCHOENEN J, et al. Zolmitriptan, a 5-ht 1B/1D receptor agonist for the acute oral treatment of mi¬graine: a multicentre, dose-range fnding study. eur J neurol 1998;5:535-43.
66. GOADSBY PJ, FERRARI MD, OLESEN J, STOVNER LJ, SENARD JM, JACKSON NC, et al. eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. neurology 2000;54:156-63.
67. ROBERT M, CABARROCAS X, FERNANDEZ FJ, ZAYAS JM, FERRER P. Almotriptan Multiple Attack Study group. efcacy and tolerability of oral almotriptan in the treatment of migraine. Cephalalgia 1998;18:406.
68. MCD AVIS HL, HUTCHINSON J; FROVATRIPTAN PHASE III INVESTIGATORS. frovatriptan - new overall clinical efcacy. Ce-phalalgia 1999;19:363-4.
69. MAUSKOP A, FARKKILA M, HERING-HANIT R, RAPOPORT A, WARNER J. Zolmitriptan is efective for the treatment of persistent and recurrent migraine headache. Curr Med Res opin 1999;15:282-9.
70. FERRARI MD, GOADSBY PJ, ROON KI, LIPTON RB. triptans (serotonin, 5-ht1B/1D agonists) in migraine: de¬tailed results and methods of meta-analysis of 53 trials. Ce-phalalgia 2002;22:633-58.
71. HALL GC, BROWN MM, MACRAE KD. triptans in mi¬graine: the risks of stroke, cardiovascular disease, and death in practice. neurology 2004;62:563-8.
72. GOLDSTEIN JA, MASSEY KD, KIRBY S, GIBSON M, et al. efect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia 2004;24:515-21.
73. FERRARI MD. how to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia 1999;19(Suppl 23):2-8.
74. GERAUD, G, KEYWOOD C, SENARSD JM. Migraine headache recurrence to clinical, pharmacological and phar-macokinetic properties of triptans. headache 2003;43:376-88.
75. LOFLAND JH, KIM SS, BATENHORST AS, JOHNSON NE, et al. Cost-efectiveness and cost-beneft of sumatriptan in patients with migraine. Mayo Clin proc 2001;76:1093-101.
76. SEEBURGER JL, TAYLOR FR, FRIEDMAN D. ef-fcacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia 2011;31:786-96. epub 2010 nov 15.
77. MACGREGOR EA, PAW S E Y S P, CAMPBELL JC, HU X. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: results of a new analysis of data from fve previously published studies. gend Med 2010;7:88-108.
78. GöBEL H. efcacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based anal-ysis. expert Rev neurother 2010;10:499-506.
79. CHEN LC, ASHCROFT DM. Meta-analysis of the efcacy and safety of zolmitriptan in the acute treatment of migraine. headache 2008;48:236-47. epub 2007 Dec 27.
80. CHEN LC, ASHCROFT DM. Meta-analysis examining the efcacy and safety of almotriptan in the acute treatment of migraine. headache 2007;47:1169-77.
81. DODICK DW, LIPTON RB, GOADSBY PJ, et al. predic¬tors of migraine headache recurrence: a pooled analysis from the eletriptan database. headache 2008;48:184-93.
82. LáINEZ MJ. Almotriptan: meeting today's needs in acute migraine treatment. expert Rev neurother 2007;7:1659-73.
83. PASCUAL J, MATEOS V, ROIG C, SANCHEZ-DEL-RIO M, JIMéNEZ D. Marketed oral triptans in the acute treat¬ment of migraine: a systematic review on efcacy and toler-ability. headache 2007;47:1152-68.
84. SEEBURGER JL, CADY RK, WINNER P. Rizatriptan for treatment of acute migraine in patients taking topira-mate for migraine prophylaxis. headache 2011; nov 11. doi: 10.1111/j.1526-4610.2011.02027.x. [epub ahead of print]
85. SEEBURGER JL, TAYLOR FR, FRIEDMAN D, et al. efcacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia 2011;31:786-96. epub 2010 nov 15.
86. TULLO V, ALLAIS G, FERRARI MD, CURONE M, et al. frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, italian study. neurol Sci 2010;31(Suppl 1):S51-4.
87. CORTELLI P, ALLAIS G, TULLO V. frovatriptan ver¬sus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, mul-ticenter, italian studies. neurol Sci 2011;32(Suppl 1):S95-8.
88. SNOW V, WEISS K, WALL EM, MOTTUR-PILSON C; AMERICAN ACADEMY OF FAMILY PHYSICIANS; AMERICAN COL¬LEGE OF PHYSICIANS - AMERICAN SOCIETY OF INTERNAL MEDICINE. pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann intern Med 20 02;137:84 0 -9.
89. TFELT -HANSENP C. published and not fully pub¬lished double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the gSK trial Register. J headache pain 2011;12:399-403. epub 2011 Mar 25.
90. CHALAUPKA FD. Acute myocardial infarction with su-matriptan: a case report and review of the literature. head¬ache 2009;49:762-4.
91. WEDER CR, SCHNEEMANN M. triptans and troponin: a case report. orphanet J Rare Dis 2009;4:15.
92. SMITH M, GOLWALA H, LOZANO P. Zolmitriptan induced acute coronary syndrome: a unique case. Am J Ter 2011;18:e153-6. doi: 10.1097/MJt.0b013e3182258e2e.
93. DOWSONA J, FUAT A, GRUFFYDD-JONES K. Clinical and economic issues associated with switching between trip-tans in clinical practice. Curr Med Res opin 2005;21:375-9.
94. BIGAL ME, TEPPER SJ. ergotamine and dihydroergot-amine: a review. Curr pain headache Rep 2003;7:55-62.
95. TFELT-HANSEN P, SAXENA PR, DAHLOF C, PAS-CUAL J, LAINEZ M, HENRY P, et al. ergotamine in the acute treatment of migraine: a review and european consen¬sus. Brain 2000;123:9-18.
96. MATHEW NT. Dosing and administration of ergotamine tartarate and dihydroergotamine. headache 1997;37(Suppl 1):26-32.
97. TOUCHON J, BERTIN L, PILGRIM AJ, ASHFORD E, BES A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of mi-graine. neurology 1996;47:361-5.
98. EVERS S, GRALOW I, BAUER B, SUHR B, BUCH-HEISTER A, et al. Sumatriptan and ergotamine overuse and drug induced headache: a clinicoepidemiologic study. Clin neuropharmacol 1999;22:201-6.
99. BEAU-SALINAS F, JONVILLE-BéRA AP, CISSOKO H, BENSOUDA-GRIMALDI L, A U T R E T- L E C A E. Drug dependence associated with triptans and ergot de¬rivatives: a case/non-case study. eur J Clin pharmacol 2010;66:413-7. epub 2009 Dec 19.
100. LIPTON RB. ergotamine tartarate and dihydroergotamine mesylate: safety profles. headache 1997;37 (Suppl 1):33-41.
101. Ad hoc Committee for the Diagnostic and Terapeutic guidelines for Migraine and Cluster headache. prophylactic treatment of migraine. J headache pain 2001;2:147-61.
102. MATHEW NT. pathophysiology of chronic migraine and mode of action of preventive medications. head¬ache 2011;51(Suppl 2):84-92. doi: 10.1111/j.1526-4610.2011.01955.x.
103. LáINEZ MJ. Te efect of migraine prophylaxis on mi-graine-related resource use and productivity. CnS Drugs 2009;23:727-38. doi: 10.2165/11314380-000000000-00000.
104. BROWN JS, PAPADOPOULOS G, NEUMANN PJ, PRICE M, FRIEDMAN M, MENZIN J. Cost-efective-ness of migraine prevention: the case of topiramate in the uK. Cephalalgia 2006;26:1473-82.
105. SILBERSTEIN SD, GOADSBY PJ. Migraine: preventive treatment. Cephalalgia 2002;22:491-512.
106. RAMADAN NM, SILBERSTEIN SD, FREITAG FG, GILBERT TT, FRISHBERG BM. evidence-Based guide¬lines in the primary Care Setting: pharmacological Manage¬ment for prevention of Migraine. Available at: http://www. aan.com. Accessed May 2003.
107. DIENER HC, KAUBE H, LIMMROTH V. A practical guide to the management and prevention of migraine. Drugs 1998;56:811-24.
108. EVERS S. treatment of migraine with prophylactic drugs. expert opin pharmacother 2008;9:2565-73.
109. SILBERSTEIN SD, DODICK D, FREITAG F, PEARL-MAN SH, HAHN SR, SCHER AI, LIP TON RB. phar¬macological approaches to managing migraine and associated comorbidities -clinical considerations for monotherapy ver¬sus polytherapy. headache 2007;47:585-99.
110. SCHROEDER BM; AAFP; ACP-ASIM. AAfp/ACp-ASiM release guidelines on the management and prevention of migraines. Am fam physician 200315;67:1392, 1395-7.
111. CHRONICLE E, MULLENERS W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004;3:CD003226.
112. MULLENERS WM, CHRONICLE EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008;28:585-97.
113. VIKELIS M, RAPOPORT AM. Role of antiepileptic drugs as preventive agents for migraine. CnS Drugs 2010;24:21-33. doi: 10.2165/11310970-000000000-00000.
114. AFSHARI D, RAFIZADEH S, REZAEI M. A compara¬tive study of the efects of low-dose topiramate versus sodium valproate in migraine prophylaxis. int J neurosci 2011; nov 2. [epub ahead of print]
115. DODICK DW, F R E I T A G F, BANKS J, SAPER J, XIANG J, RUPNOW M, BIONDI D, GREENBERG SJ, HULI-HAN J. topiramate versus amitriptyline in migraine pre¬vention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ter 2009;3:542-59.
116. SILBERSTEIN SD, LIP TON RB, DODICK DW, FRE-ITAGF G, RAMADAN N, MATHEW N, BRANDES JL, BIGAL M, SAPER J, ASCHER S, JORDAN DM, GREENBERG SJ, HULIHAN J; TOPIRAMATE CHRONIC MI¬GRAINE STUDY GROUP. efcacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. headache 2007;47:170-80.
117. SILBERSTEIN S, LIPTON R, DODICK D, FREITAG F, MATHEW N, BRANDES J, BIGAL M, ASCHER S, MOREIN J, WRIGHT P, GREENBERG S, HULIHAN J. topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efcacy measures. headache 2009;49:1153-62.
118. DODICK DW, SILBERSTEIN SD. Migraine prevention. pract neurol 2007;7:383-93.
119. EVANS RW, ROSEN N. expert opinion: migraine, psychi¬atric comorbidities, and treatment. headache 2008;48:952-8.
120. LIMMROTH V, MICHEL MC. Te prevention of mi¬graine: a critical review with special emphasis on beta-adreno-receptor blockers. Br J Clin pharmacol 2001;52:237-43.
121. ANDERSON K, VINGE E. Beta-adrenoreceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 1990;39:355-73.
122. HOLROYD KA, PENZIEN DB, COORDINGLEY GE. propranolol in the management of recurrent migraine: a me-ta-analytic review. headache 1991;31:333-40.
123. JACKSON JL, SHIMEALL W, SESSUMS L, et al. tricy-clic antidepressants and headaches: systematic review and me-ta-analysis. BMJ 2010;341:c5222. doi: 10.1136/bmj.c5222.
124. COUCH JR, HASSANEIN RS. Amitriptyline in migraine prophylaxis. Arch neurol 1979;36:695-9.
125. MATHEW NT. prophylaxis of migraine and mixed head¬ache. A randomized controlled study. headache 1981;21:105-9.
126. TARLACI S. escitalopram and venlafaxine for the prophy-laxis of migraine headache without mood disorders. Clin neuropharmacol 2009;32:254-8.
127. OZYALCIN SN, TALUG K, KIZILTAN E, YUCEL B, ERTAS M, DISCI R. Te efcacy and safety of venlafaxine in the prophylaxis of migraine. headache 2005;45:144-52.
128. CUSI C, STERZI RR, CANEPARI C. Selective sero¬tonin re-uptake inhibitors (SSRis) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005;3:CD002919.
129. BANK J. A comparative study of amitriptyline and fuvoxam-ine in migraine prophylaxis. headache 1994;34:476-8.
130. OGUZHANOGLU A, SAHINER T, KURT T, AKALIN O. use of amitriptyline and fuoxetine in prophylaxis of mi¬graine and tension type headache. Cephalalgia 1999;19:531-2.
131. EVANS RW, TEPPER SJ, SHAPIRO RE, SUN-EDEL-STEIN C, TIETJEN GE. Te fDA alert on serotonin syn¬drome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American headache Society position pa¬per. headache 2010;50:1089-99.
132. DIENER HC, FöH M, IACCARINO C , et al. Cyclande-late in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propra-nolol. Cephalalgia 1996;16:441-7.
133. DIAMOND S, FREITAG FG. A double blind trial of funa-rizine in migraine prophylaxis. headache 1993;4:169-72.
134. MENDENOPOULOS G, MANAFI T, LOGOTHETIS I, BOSTANTJOPOILOU S. flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cepha-lalgia 1985;5:31-7.
135. SORENSEN PS, LARESN BH, RASMUSSEN MJ, et al. flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efcacy and tolerability. headache 1991;10:657.
136. CLELAND PG, BARNES D, ELRINGTON GM, et al. Studies to assess if pizotifen prophylaxis improves migraine beyond the beneft ofered by acute sumatriptan therapy alone. eur neurol 1997;38:31-8.
137. SILBERSTEIN SD. Methysergide. Cephalalgia 1998;18:421-35.
138. RASCOL A, MONTASTRUC JL, RASCOL O. flunariz-ine versus pizotifen: a double-blind study in the prophylaxis of migraine. headache 1986;26:83-5.
139. FORSSMAN B, HENRIKSSON KG, KIHLSTRAND S . A comparison between BC105 and methysergide in the pro-phylaxis of migraine. Acta neurol Scand 1972;48:204-12.
140. VILMING S, STANDNES B, HEDMAN C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine: a double-blind investigation. Cephalalgia 1985;5:17-23.
141. BEHAN PO, REID M. propranolol in the treatment of mi-graine. practitioner 1980;224:201-4.
142. HERING R, KURITZKY A. Sodium valproate in the pro-phylactic treatment of migraine: a double-blind study versus palcebo. Cepahalalgia 1992;12:81-4.
143. KLAPPER JA. Divalproex sodium in migraine prophylaxis: a dose controlled study. Cephalalgia 1997;17:103-8.
144. JENSEN R, BRINCK T, OLESEN J. Sodium valproate has a prophylactic efect in migraine without aura. neurology 1994;44:647-51.
145. KANIECKI RG. A comparison of divalproex with propra-nolol and placebo for the prophylaxis of migraine without aura. Arch neurol 1997;54:1141-5.
146. ADELMAN J, FREITAGF G, LAINEZ M. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled tri¬als. pain Med 2008;9:175-85.
147. DIENER HC, BUSSONE G, VAN OENE JC. topira-mate reduces headache days in chronic migraine: a random¬ized, double-blind, placebo-controlled study. Cephalalgia 2007;27:814-23. epub 2007 Apr 18.
148. POTTER DL, HART DE, CALDER CS, STOREY JR. A double-blind, randomized, placebo-controlled, parallel study to determine the efcacy of topiramate in the prophylactic treatment of migraine. neurology 2000;54:A15. (abstract)
149. EDWARDS KR, GLANTZ MJ, SHEA P, NORTON JA, CROSS N. A double blind, randomized trial of topiramate versus placebo in the prophylactic treatment of migraine head¬ache with and without aura. Cephalalgia 2000;20:316. (ab¬stract)
150. MATHEW NT, RAPOPORT A, SAPER J, MAGNUS L, KLAPPER J, RAMADAN N , et al. efcacy of gabapentin in migraine prophylaxis. headache 2001;41:119-28.
151. VUKOVIC V, LOVRENCIC-HUZJAN A, BOSNAR-PURETIC M, DEMARIN V. Te efcacy of gabapentin in migraine prophylaxis: an observational open label study. Acta Clin Croat 2009;48:145-51.
152. WESSELY P, BAUMGARTNER C, KLINGER D, KRECZI J, MEYERSON N, SAILER L, et al. preliminary results of a double-blind study with the new migraine prophy¬lactic drug gabapentin. Cephalalgia 1987;7:477-8.
153. PIZZOLATO R, VILLANI V, PROSPERINI L, CIUF-FOLI A, SETTE G. efcacy and tolerability of pregabalin as preventive treatment for migraine: a 3-month follow-up study. J headache pain 2011;12:521-5. epub 2011 Apr 9.
154. CALANDRE EP, GARCIA-LEIVA JM, RICO-VILLA-DEMOROS F, VILCHEZ JS, RODRIGUEZ-LOPEZ CM. pregabalin in the treatment of chronic migraine: an open-label study. Clin neuropharmacol 2010;33:35-9.
155. STEINER TJ, FINDLEY LJ, YUEN AW. lamotrigine ver¬sus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997;17:109-12.
156. LAMPL C, BUZATH A, KLINGER D, NEUMANN K . lamotrigine in the prophylactic treatment of migraine aura -a pilot study. Cephalalgia 1999;19:58-63.
157. GUPTA P, SINGH S, GOYAL V, SHUKLA G, BEHARI M. low-dose topiramate versus lamotrigine in migraine pro¬phylaxis (the lotolamp study). headache 2007;47:402-12.
158. BRIGHINA F, PALERMO A, ALOISIO A, FRANCO-LINI M, GIGLIA G, FIERRO B. levetiracetam in the pro¬phylaxis of migraine with aura: a 6-month open-label study. Clin neuropharmacol 2006;29:338-42.
159. PIZZA V, BUSILLO V, AGRESTA A, BISOGNO A, CAPASSO A. elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam. Cent nerv Syst Agents Med Chem 2011;11:31-4.
160. BERAN RG, SPIRA PJ. levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (Te Australian KeppRA headache trial [AuS-Kht]). Cephalalgia 2011;31:530-6. epub 2010 nov 8.
161. O'NEAL B P , MANN JD. Aspirin prophylaxis in migraine. lancet 1978;2:1179-81.
162. MASEL BE, CHESSON AL, PETERS BH, LEVIN HS, ALPERIN JB. platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole. headache 1980;20:13-8.
163. SALOMON GD, KUNKEL RS. flurbiprofen in the pro¬phylaxis of migraine. Cleve Clin J Med 1993;60:43-8.
164. SANCES G, MARTIGNONI E, FIORONI L, BLAN-DINI F, FACCHINETII F, NAPPI G. naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. headache 1990;30:705-9.
165. SZEKEL B, MERRYMAN S, CROFT H, POST G. pro¬phylactic efect of naproxen sodium on perimenstrual head¬ache: a double blind placebo controlled study. Cephalalgia 1989;9(Suppl 10):452-3.
166. MACEDO A, BAñOS JE, FARRé M. placebo response in the prophylaxis of migraine: a meta-analysis. eur J pain 2008;12:68-75. epub 2007 Apr 23.
167. SCHIAPPARELLI P, ALLAIS G, CASTAGNOLI GA-BELLARI I, ROLANDO S, TERZI MG, BENEDETTO C. non-pharmacological approach to migraine prophylaxis: part ii. neurol Sci 2010;31(Suppl 1):S137-9.
168. SUN-EDELSTEIN C, MAUSKOP A. foods and supple¬ments in the management of migraine headaches. Clin J pain 2009;25:446-52.
169. EVANS RW, TAYLOR FR. "natural" or alternative medica¬tions for migraine prevention. headache 2006;46:1012-8.
170. SCHOENEN J, JACQUY J, LENAERTS M. efectiveness of high-dose ribofavin in migraine prophylaxis. A random¬ized controlled trial. neurology 1998;50:466-70.
171. BOEHNKE C, REU TER U, FLACH U, SCHUH-HOFER S, EINHäUPL KM, ARNOLD G. high-dose ribofavin treatment is efcacious in migraine prophylaxis: an open study in a tertiary care centre. eur J neurol 2004;11:475-7.
172. MAIZELS M, BLUMENFELD A, BURCHETTE R. A combination of ribofavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. headache 2004;44:885-90.
173. VOLGER BK, PITTLER MH, ERNST E. feverfew as a preventive treatment for migraine: a systematic review. Ce-phalalgia 1998;18:704-8.
174. PFAFFENRATH V, DIENER HC, FISCHER M, FRIE-DE M, HENNEICKE-VON ZEPELIN HH. Te efcacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis -a double blind, multicentre, randomized place¬bo-controlled dose-response study. Cephalalgia 2002;22:523-32.
175. PITTLER MH, ERNST E. feverfew for preventing mi¬graine. Cochrane Database Syst Rev 2004;1:CD002286.
176. TM M) in the treatment of migraine. headache 2011;51:1078-86. doi: 10.1111/j.1526-4610.2011.01910.x. epub 2011 Jun 1.
177. BOSKA MD, WELCH KMA, BARKER PB, NELSON JA, SCHULTZ L. Contrasts in cortical magnesium, phos-pholipid and energy metabolism between migraine syndromes. neurology 2002;58:1227-33.
178. PEIKERT A, WILIMZIG C, KöHNE-VOLLAND R . prophylaxis of migraine with oral magnesium: results from a prospective multi-center, placebo-controlled and double blind randomized study. Cephalalgia 1996;16:257-63.
179. MAUSKOP A, ALTURA BT, CRACCO RQ, ALTURA BM. intravenous magnesium sulfate relieves acute migraine in patients with low serum ionized magnesium levels. neurol-ogy 1995;45:A379. (abstract)
180. KöSEOGLU E, TALASLIOGLU A, GöNüL AS, KULA M. Te efects of magnesium prophylaxis in migraine without aura. Magnes Res 2008;21:101-8.
181. BIGAL ME, BORDINI CA, TEPPER SJ, SPECIALI JG. intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A random-ized, double-blind, placebo-controlled study. Cephalalgia 2002;22:345-53.
182. ROZEN TD, OSHINSKY ML, GEBELINE CA, BRADLEY KC, YOUNG WB, SCECHTER AL, SILBER-STEIN SD. open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-41.
183. SáNDOR PS, DI CLEMENTE L, COPPOLA G. efcacy of coenzyme Q10 in migraine prophylaxis: a randomized con¬trolled trial. neurology 2005;64:713-5.
184. D'ANDREA G, BUSSONE G, ALLAIS G. efcacy of ginkgolide B in the prophylaxis of migraine with aura. neurol Sci 2009;30(Suppl 1):S121-4.
185. SILBERSTEIN S, MATHEW N, SAPER J, JENKINS S . Botulinum toxin type A as a migraine preventive treatment. headache 2000;40:445-50.
186. BRIN MF, SWOPE DM, O'BRIAN C, ABBASI S, POGO-DA JM. Botox for migraine: double-blind, placebo-controlled, region specifc evaluation. Cephalalgia 2000;20:421-2.
187. BINDER WJ, BRIN MF, BLITZER A, SCHOENROCK LD, POGODA JM. Botulinum toxin type A (BotoX) for treatment of migraine headaches: an open-label study. otolar-yngol head neck Surg 2000;123:669-76.
188. JACKSON JL, KURIYAMA A, HAYASHINO Y . Botu-linum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA 2012;307:1736-45.
189. AURORA SK, GAWEL M, BRANDES JL, et al. Botuli-num toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. headache 2007;47:486-99.
190. DIENER HC, DODICK DW, AURORA SK. onabotu-linumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the pReeMpt 2 trial. Cephalalgia 2010;30:804-14. epub 2010 Mar 17.
191. CADY RK, SCHREIBER CP, PORTER JA, BLUMEN-FELD AM, FARMER KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. head¬ache 2011;51:21-32. doi: 10.1111/j.1526-4610.2010.01796.x. epub 2010 nov 10.
192. GOBEL H. Botulinum toxin in migraine prophylaxis. J neu-rol 2004;251(Suppl 1):8-11.
193. EFTEDAL OS, LYDERSEN S, HELDE G, WHITE L, BRUBAKK AO, STOVNER LJ. A randomized, double blind study of the prophylactic efect of hyperbaric oxygen therapy on migraine. Cephalalgia 2004;24:639-44.
194. MYERS DE, MYERS RA. A preliminary report on hyper-baric oxygen in the relief of migraine headache. headache 1995;35:197-9.
195. WILSON JR, FORESMAN BH, GAMBER RG, WRIGHT T. hyperbaric oxygen in the treatment of mi¬graine with aura. headache 1998;38:112-5.
196. BENNETT MH, FRENCH C, SCHNABEL A, WASIAK J, KRANKE P. normobaric and hyperbaric oxygen therapy for migraine and cluster headache. Cochrane Database Syst Rev 2008;3:CD005219.
197. SILBERSTEIN SD, PERES MF, HOPKINS MM, SHECHTER AL, YOUNG WB, ROZEN TD. olanzap-ine in the treatment of refractory migraine and chronic daily headache. headache 2002;42:515-8.
198. HONKANIEMI J, LIIMATAINEN S, RAINESALO S, SULAVUORI S. haloperidol in the acute treatment of mi¬graine: a randomized, double-blind, placebo-controlled study. headache 2006;46:781-7.
199. LIPTON RB, SILBERSTEIN SD, SAPER JR, BIGAL ME, GOADSBY PJ. Why headache treatment fails. neurol¬ogy 2003;60:1064-70.
200. AD HOC COMMITTEE FOR THE DIAGNOSTIC AND TERAPEUTIC GUIDELINES FOR MIGRAINE AND CLUSTER HEADACHE. prophylactic treatment of migraine. J headache pain 2001;2:162-7.
201. GRAZZI L, ANDRASIK F. non-pharmacological ap¬proaches in migraine prophylaxis: behavioral medicine. neu-rol Sci 2010;31(Suppl 1):S133-5.
202. BROWN JM. imagery coping strategies in the treatment of migraine. pain 1984;18:157-67.
203. SORBI M, TELLEGEN B. Diferential efects of training in relaxation and stress-coping in patients with migraine. head¬ache 1986;26:473-81.
204. D'SOUZA PJ, LUMLEY MA, KRAF T CA, DOOLEY JA. Relaxation training and written emotional disclosure for tension or migraine headaches: a randomized, controlled trial. Ann Behav Med 2008;36:21-32. epub 2008 Aug 12.
205. BLANCHARD EB, APPELBAUM KA, RADNITZ CL, MORRILL B, MICHULTKA D, KIRSCH C , et al. A con¬trolled evaluation of thermal biofeedback combined with cog¬nitive therapy in the treatment of vascular headache. J Consult Clin psychol 1990;58:216-24.
206. BLANCHARD EB, APPELBAUM KA, NICHOLSON NL, RADNITZ CL, et al. A controlled evaluation of the addition of cognitive therapy to a home-based biofeedback and relaxation treatment of vascular headache. headache 1990;30:371-6.
207. MARCUS DA, SCHARFF L, MERCER S, TURK D C . nonpharmacological treatment for migraine: incremental utility of physical therapy with relaxation and thermal bio-feedback. Cephalalgia 1998;18:266-72.
208. MULLALLY WJ, HALL K, GOLDSTEIN R. efcacy of biofeedback in the treatment of migraine and tension type headaches. pain physician 2009;12:1005-11.
209. NESTORIUC Y, MARTIN A, RIEF W, ANDRASIK F. Biofeedback treatment for headache disorders: a com-prehensive efcacy review. Appl psychophysiol Biofeedback 2008;33:125-40. epub 2008 Aug 26.
210. KISCH I. hypnosis as an adjunct to cognitive-behavioral psychotherapy: a meta-analysis. J Consult Clin psychol 1995;63:214-20.
211. CHAIBI A, TUCHIN PJ, RUSSELL MB. Manual thera¬pies for migraine: a systematic review. J headache pain 2011;12:127-33. epub 2011 feb 5.
212. VUKOVIC V, PLAVEC D, LOVRENCIC-HUZJAN A, GALINOVIC I, ALEKSIC-SHIHABI A, DEMARIN V. Migrena i hormonski utjecaji. Acta Med Croat 2008;62:141-4. (in Croatian)
213. ENDRES HG, DIENER HC, MOLSBERGER A. Role of acupuncture in the treatment of migraine. expert Rev neu-rother 2007;79:1121-34.
214. DIENER HC, KRONFELD K, BOEWING G. efcacy of acupuncture for the prophylaxis of migraine: a multi-centre randomised controlled clinical trial. lancet neurol 2006;5:310-6.
215. ALECRIM-ANDRADE J, MACIEL-JúNIOR JA, CAR-Nè X, SEVERINO VASCONCELOS GM, CORREA-FILHO HR. Acupuncture in migraine prevention: a ran¬domized sham controlled study with 6-month posttreatment follow-up. Clin J pain 2008;24:98-105.
216. LINDE K, ALLAIS G, BRINKHAUS B, MANHEIMER E, VICKERS A, WHITE AR. Acupuncture for migraine pro¬phylaxis. Cochrane Database Syst Rev 2009;1:CD001218.
217. PARKER GB, TUPLING H, PRYOR DS. A controlled trial of cervical manipulation of migraine. Aust n Z J 1978;8:589-93.
218. NELSON CF, BRONFORT G, EVANS R. Boline p, golDSMith C, AnDeRSon R. Te efcacy of spinal manipulation, amitriptyline and the combination of both therapies for the prophylaxis of migraine headache. J Manipu¬lative physiol Ter 1998;21:511-9.
219. MACGREGOR EA, VICTOR TW, HU X, XIANG Q, PUENPATOM RA, CHEN W, CAMPBELL JC. Char¬acteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. headache 2010;50:528-38.
220. VUKOVIC-CVETKOVIC V, PLAVEC D, LOVRENCIC HUZJAN A, GALINOVIC I, ŠERIC V, DEMARIN V. is iron defciency anemia related to menstrual migraine? post hoc analysis of an observational study evaluating clinical characteristics of patients with menstrual migraine. Acta Clin Croat 2010;49:389-94.
221. BOUSSER MG, CONRAD J, KITTNER S, DE LIGNIERES B, MACGREGOR EA, MASSIOU H, SIL-BERSTEIN SD, TZOURIO C. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. Cephalalgia 2000;20:155-6.
222. MASSIOU H, MACGREGOR FA. evolution and treat¬ment of migraine with oral contraceptives. Cephalalgia 2000;20:170-4.
223. DENNERSTEIN L, MORSE C, BURROWS G, OATS J , et al. Menstrual migraine: a double-blind trial of percutaneous estradiol. gynecol endocrinol 1988;2:113-20.
224. PFAFFENRATH V. efcacy and safety of percutane¬ous estradiol vs. placebo in menstrual migraine. Cephalalgia 1993;13(Suppl 13):244.
225. Institute For Clinical SYSTEMS IMPROVEMENT (ICSI). Migraine headache. Available at: http://www.neurology.org. Accessed May 2003.
226. BECKER J. use of oral contraceptives in patients with mi-graine. neurology 1999;53(Suppl 1):19-25.
227. PRINGSHEIM T, DAVENPORT WJ, DODICK D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. neurology 2008;70:1555-63.
228. MACGREGOR EA. prevention and treatment of menstrual migraine. Drugs 2010;70:1799-818. doi: 10.2165/11538090-000000000-00000.
229. SILBERSTEIN SD, DELIGNIERES B. Migraine, meno¬pause and hormonal replacement therapy. Cephalalgia 2000;20:214-21.
230. MACGREGOR EA. Migraine headache in perimeno-pausal and menopausal women. Curr pain headache Rep 2009;13:399-403.
231. NAPPI RE, SANCES G, DETADDEI S, ORNATI A, CHIOVATO L, POLATTI F. hormonal management of migraine at menopause. Menopause int 2009;15:82-6.
232. SCHüRKS M, RIST PM, BIGAL ME, BURING JE, LIP-TON RB, KURTH T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914. doi: 10.1136/bmj.b3914.
233. CURTIS KM, MOHLLAJEE AP, PETERSON HB. use of combined oral contraceptives among women with migraine and nonmigrainous headaches: a systematic review. Contra-ception 2006;73:189-94. epub 2005 oct 21.
234. SCHWEDT TJ, DEMAERSCHALK BM, DODICK DW. patent foramen ovale and migraine: a quantitative sys¬tematic review. Cephalalgia 2008;28:531-40. epub 2008 Mar 17.
235. CRIPE SM, FREDERICK IO, QIU C, WILLIAMS MA. Risk of preterm delivery and hypertensive disorders of preg¬nancy in relation to maternal co-morbid mood and migraine disorders during pregnancy. paediatr perinat epidemiol 2011;25:116-23. doi: 10.1111/j.1365-3016.2010.01182.x. epub 2011 Jan 14.
236. SANCES G, GRANELLA F, NAPPI RE, FIGNON A, GHIOTTO N, POLATTI F, NAPPI G. Course of mi¬graine during pregnancy and postpartum: a prospective study. Cephalalgia 2003;23:197-205.
237. NAPPI RE, ALBANI F, SANCES G, TERRENO E, BRAMBILLA E, POLATTI F. headaches during preg¬nancy. Curr pain headache Rep 2011;15:289-94.
238. MARCUS DA. Managing headache during pregnancy and lactation. expert Rev neurother 2008;8:385-95.
239. AIROLA G, ALLAIS G, CASTAGNOLI GABELLARI I, ROLANDO S, MANA O, BENEDETTO C. n o n -pharmacological management of migraine during pregnancy. neurol Sci 2010;31(Suppl 1):S63-5.
240. CASSINA M, DI GIANANTONIO E, TOLDO I, B AT -TISTELLA PA, CLEMENTI M. Migraine therapy during pregnancy and lactation. expert opin Drug Saf 2010;9:937-48.
241. RASMUSSEN BK, JENSEN R, OLESEN J. A population-based analysis of the diagnostic criteria of Te international headache Society. Cephalalgia 1991;11:129-34.
242. GOADSBY PJ, BOES C. Chronic daily headache. J neurol neurosurg psychiatry 2002;72(Suppl 2):2-5.
243. RUSSELL MB. genetics of tension-type headache. J head¬ache pain 2007;8:71-6. epub 2007 May 11.
244. ASHINA M, BENDTSEN L, JENSEN R, SAKAI F, OLESEN J. Muscle hardness in patients with chronic ten¬sion-type headache: relation to actual headache state. pain 1999;79:201-5.
245. JENSEN R, BENDSEN L, OLESEN J. Muscular fac¬tors are of importance in tension-type headache. headache 1998;38:10-7.
246. BENDSEN L. Central sensitization in tension-type head¬ache -possible pathophysiological mechanisms. Cephalalgia 2000;20:486-508.
247. JENSEN R, OLESEN J. tension-type headache: an up¬date on mechanisms and treatment. Curr opin neurol 2000;13:285-9.
248. HOLROYD KA, O'DONELL FJ, ST ENSLAND M, LIPCHIK GL, et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination. A randomized controlled trial. J Am Med Assoc 2001;285:2208-15.
249. BENDSEN L, EVERS S, LINDE M, MITSIKOSTAS DD, SANDRINI G, SCHOENEN J; EFNS. efnS guide¬line on the treatment of tension-type headache -report of an efnS task force. eur J neurol 2010;17:1318-25. doi: 10.1111/j.1468-1331.2010.03070.x.
250. LENAERTS ME. pharmacoprophylaxis of tension-type headache. Curr pain headache Rep 2005;9:442-7.
251. CERBO R, BARBANTI P, FABBRINI G, et al. Amitrip-tyline is efective in chronic but not in episodic tension-type headache: pathogenic implications. headache 1998;38:453-7.
252. BENDSEN L, JENSEN R. treating tension-type headache -an expert opinion. expert opin pharmacother 2011;12:1099-109. epub 2011 Jan 20.
253. ALEKSIC-SHIHABI A, LOJEN G, VUKOVIC V . pre -vencija tenzijske glavobolje topiramatom. Acta Med Croat 2008;62:145-9. (in Croatian)
254. SPIRA PJ, BERAN RG; AUSTRALIAN GABAPENTIN CHRONIC DAILY HEADACHE GROUP. gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. neurology 2003;61:1753-9.
255. YUREKLI VA, AKHAN G, KUTLUHAN S, UZAR E, KOYUNCUOGLU HR, GULTEKIN F. Te efect of sodi¬um valproate on daily headache and its subgroups. J headache pain 2008;9:37-41. epub 2008 Jan 23.
256. LAMPL C, MARECEK S, M AY A, BENDSEN L. A pro¬spective, open-label, long-term study of the efcacy and toler-ability of topiramate in the prophylaxis of chronic tension-type headache. Cephalalgia 2006;26:1203-8.
257. ASHKENAZI A, SILBERSTEIN S. is botulinum toxin useful in treating headache? yes. Curr treat options neurol 2009;11:18-23.
258. OBERMANN M, DIENER HC. is botulinum toxin use¬ful in treating headache? no. Curr treat options neurol 2009;11:24-31.
259. ONDO WG, VUONG KD, DERMAN HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004;24:60-5.
260. RELJA M, TELAROVIC S. Botulinum toxin in tension-type headache. J neurol 2004;251(Suppl 1):12-4.
261. SCHULTE-MATTLER WJ, WIESER T, ZIERZ S. treat¬ment of tension-type headache with botulinum toxin. A pilot study. eur J Med Res 1999;4:183-6.
262. RELJA M. treatment of tension-type headache with botuli-num toxin: 1 year-follow-up. Cephalalgia 2000;20:236.
263. PADBERG M, DE BRUIJN SFTM, DE HAAN RJ, TAV Y DL. treatment of chronic tension-type headache with botu-linum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004;24:675-80.
264. SCHULTE-MATTLER WJ, MARTINEZ-CASTRIL-LO JC. Botulinum toxin therapy of migraine and tension-type headache: comparing diferent botulinum toxin prepara¬tions. eur J neurol 2006;13(Suppl 1):51-4.
265. LINDE K, ALLAIS G, BRINKHAUS B, MANHEIMER E, VICKERS A, WHITE AR. Acupuncture for tension-type headache. Cochrane Database Syst Rev 2009;1:CD007587.
266. MANZONI GC, MICIELI G, GRANELLA F, TAS-SORELLI C, ZANFERRARI C, CAVALLINI A. Cluster headache-course over ten years in 189 patients. Cephalalgia 1991;11:169-74.
267. SJöSTRAND C, WALDENLIND E, EKBOM K. A fol¬low-up study of 60 patients after an assumed frst period of cluster headache. Cephalalgia 2000;20:653-7.
268. EKBOM K. patterns of cluster headache with a note on the relations to angina pectoris and peptic ulcer. Acta neurol Scand 1970;46:225-37.
269. FISCHERA M, MARZINIAK M, GRALOW I, EVERS S. Te incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia 2008;28:614-8.
270. TE SUMATRIPTAN CLUSTER HEADACHE STUDY GROUP. treatment of acute cluster headache with sumatriptan. n engl J Med 1991;325:322-6.
271. EKBOM K, MONSTAD I, PRUSINSKI A, COLE JA, PILGRIM AJ, NORONHA D. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Te Sumatriptan Cluster headache Study group. Acta neurol Scand 1993;88:63-9.
272. VAN VLIET JA , BAHRA A, MARTIN V, RAMADAN N, AURORA SK, MATHEW N T , et al. intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. neurology 2003;60:630-3.
273. BAHRA A, GAWEL MJ, HARDEBO JE, MILLSON D, BREEN SA, GOADSBY PJ. oral zolmitriptan is efec-tive in the acute treatment of cluster headache. neurology 2000;54:1832-9.
274. CITTADINI E, MAY A, STRAUBE A, EVERS S, BUS-SONE G, GOADSBY PJ. efectiveness of intranasal zol-mitriptan in acute cluster headache: a randomized, place¬bo-controlled, double-blind crossover study. Arch neurol 2006;63:1537-42.
275. RAPOPORT AM, MATHEW NT, SILBERSTEIN SD, DODICK D, TEPPER SJ, SHEFTELL FD, et al. Zolmi-triptan nasal spray in the acute treatment of cluster headache: a double-blind study. neurology 2007;69:821-6.
276. FOGAN L. treatment of cluster headache: a double blind comparison of oxygen vs. air inhalation. Arch neurol 1985;42:362-3.
277. COHEN A, BURNS B, GOADSBY P. high fow oxygen for treatment of cluster headache. JAMA 2009;302:2451-7.
278. ANDERSSON PG, JESPERSEN LT. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo. Cephalalgia 1986;6:51-4.
279. MAGNOUX E, ZLOTNIK G. outpatient intravenous di-hydroergotamine for refractory cluster headache. headache 2004;44:249-55.
280. ROBBINS L. intranasal lidocaine for cluster headache. headache1995;35:83-4.
281. COSTA A, PUCCI E, ANTONACI F , et al. Te efect of intranasal cocaine and lidocaine on nitroglycerin induced at¬tacks in cluster headache. Cephalalgia 2000;20:85-91.
282. MATHARU MS, LEVY MJ, MEERAN K , et al. Subcu¬taneous octreotide in cluster headache: randomized place-bo-controlled double-blind crossover study. Ann neurol 2004;56:488-94.
283. ROZEN TD. olanzapine as an abortive agent for cluster headache. headache 2001;41:813-6.
284. LEONE M, D'AMICO D, FREDIANI F , et al. verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. neurology 2000;54:1382-5.
285. ANTONACI F, COSTA A, CANDELORO E , et al. Single high-dose steroid treatment in episodic cluster headache. Ce-phalalgia 2005;25:290-5.
286. ANTHONY M, DAHER BN. Mechanism of action of ste¬roids in cluster headache. in: Rose fC, editor. new advances in headache research, 2. london: Smith-gordon, 1992;271-4.
287. AMBROSINI A, VANDENHEEDE M, ROSSI P , et al. Suboccipital injection with a mixture of rapid-and long-acting steroids in cluster headache: a double-blind placebo-controlled study. pain 2005;118:92-6.
288. LEROUX E, VALADE D, TAIFAS I, VICAUT E, CHA-GNON M, ROOS C, DUCROS A. Suboccipital steroid in¬jections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. lancet neurol 2011;10:891-7.
289. BUSSONE G, LEONE M, PECCARISI C, MICIELI G, GRANELLA F, MAGRI M, MANZONI GC, NAPPI G. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. headache 1990;30:411-7.
290. CURRAN DA, HINTERBERGER H, LANCE J W . Methysergide. Res Clin Stud headache 1967;1:74.
291. KRABBE A. limited efcacy of methysergide in cluster headache. A clinical experience. Cephalalgia 1989;9:404-5.
292. EKBOM K. prophylactic treatment of cluster headache with a new serotonin antagonist, BC 105. Acta neurol Scand 1969;45:601-10.
293. GALLAGHER RM, MUELLER LL, FREITAG FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am osteopath Assoc 2002;102:92-4.
294. HERING R, KURITZKY A. Sodium valproate in the treat¬ment of cluster headache: an open clinical trial. Cephalalgia 1989;9:195-8.
295. EL AMRANI M, MASSIOU H, BOUSSER MG. A nega¬tive trial of sodium valproate in cluster headache: method¬ological issues. Cephalalgia 2002;22:205-8.
296. WHEELER SD, CARRAZANA EJ. topiramate-treated cluster headache. neurology 1999;53:234-6.
297. LáINEZ MJ, PASCUAL J, PASCUAL AM, SANTONJA JM, PONZ A, SALVADOR A. topiramate in the prophylac¬tic treatment of cluster headache. headache 2003;43:784-9.
298. SCHUH-HOFER S, ISRAEL H, NEEB L, et al. Te use of gabapentin in chronic cluster headache patients refractory to frst-line therapy. eur J neurol 2007;14:694-6.
299. LEANDRI M, LUZZANI M, CRUCCU G, et al. Drug resistant cluster headache responding to gabapentin: a pilot study. Cephalalgia 2001;21:744-6.
300. LEONE M, D'AMICO D, MOSCHIANO F, FRASCHI-NI F, BUSSONE G. Melatonin versus placebo in the pro¬phylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 1996;16:494-6.
301. PRINGSHEIM T, MAGNOUX E, DOBSON CF, HAMEL E, AUBE M. Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. headache 2002;42:787-92.
302. MATHER PJ, SILBERSTEIN SD, SCHULMAN EA, HOPKINS MM. Te treatment of cluster headache with repetitive intravenous dihydroergotamine. headache 1991;31:525-32.
303. MAGNOUX E, ZLOTNIK G. outpatient intravenous di-hydroergotamine for refractory cluster headache. headache 2004;44:249-55.
304. MARKS DR, RAPOPORT A, PADLA D, WEEKS R, ROSUM R, SHEFTELL F, ARROWSMITH F. A dou¬ble-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia 1993;13:114-6.
305. SAPER JR, KLAPPER J, MATHEW NT, RAPOPORT A, PHILLIPS SB, BERNSTEIN JE. intranasal civamide for the treatment of episodic cluster headaches. Arch neurol 2002;59:990-4.
306. D'ANDREA G, PERINI F, GRANELLA F , et al. efcacy of transdermal clonidine in short-term treatment of cluster headache: a pilot study. Cephalalgia 1995;15:430-3.
307. LEONE M, ATTANASIO A, GRAZZI L, et al. transder-mal clonidine in the prophylaxis of episodic cluster headache: an open study. headache 1997;37:559-60.
308. DODICK DW, ROZEN TD, GOADSBY PJ, SILBER-STEIN SD. Cluster headache. Cephalalgia 2000;20:787-803.
309. FONTAINE D, CHRISTOPHE SOL J, RAOUL S, FA-BRE N, GERAUD G, MAGNE C, SAKAROVITCH C , LANTERI-MINET M. treatment of refractory chronic cluster headache by chronic occipital nerve stimulation. Ce-phalalgia 2011;31:1101-5.
310. LEONE M, FRANZINI A, CECCHINI AP, BROGGI G, BUSSONE G. hypothalamic deep brain stimulation in the treatment of chronic cluster headache. Ter Adv neurol Disord 2010;3:187-95.
311. FONTAINE D, LAZORTHES Y, MERTENS P, BLOND S, GéRAUD G, FABRE N, NAVEZ M, LUCAS C, DUBOIS F, GONFRIER S, PAQUIS P, LANTéRI-MINET M. Safety and efcacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. J headache pain 2010;11:23-31.
312. KANO H, KONDZIOLKA D, MATHIEU D, STAFFORD SL, FLANNERY TJ, NIRANJAN A, POLLOCK BE, KAUFMANN AM, FLICKINGER JC, LUNSFORD L D . Stereotactic radiosurgery for intractable cluster headache: an initial report from the north American gamma Knife Con¬sortium. J neurosurg 2011;114:1736-43.
313. JARRAR RG, BLACK DF, DODICK D W , et al. o utcome of trigeminal nerve section in the treatment of chronic cluster headache. neurology 2003;60:1360-2.
314. TAHA JM, TEW JM JR. long-term results of radiofrequen-cy rhizotomy in the treatment of cluster headache. headache 1995;35:193-6.
315. MATHARU MS, GOADSBY PJ. persistence of attacks of cluster headache after trigeminal nerve root section. Brain 2002;125:976-84.
316. ROSSELLI JL, KARPINSKI JP. Te role of lamotrigine in the treatment of short-lasting unilateral neuralgiform head¬ache attacks with conjunctival injection and tearing syndrome. Ann pharmacother 2011;45:108-13.
317. ARROYO AM, DURáN XR, BELDARRAIN MG, PINEDO A, GARCíA-MONCó JC. Response to intrave¬nous lidocaine in a patient with SunCt syndrome. Cephala-lgia 2010;30:110-2.